by Clinical Neuropsychologist | Friday, November 22, 2024 | Dementia
Abstract INTRODUCTION Idiopathic normal pressure hydrocephalus (iNPH) and cerebral small vessel disease (CVSD) are age-related diseases, but their prevalence and clinical relationship are unclear. METHODS This prospective cohort study enrolled 95 patients with...
by Clinical Neuropsychologist | Friday, November 22, 2024 | Dementia
Abstract INTRODUCTION In the research setting, obtaining accurate established biomarker measurements and maximizing use of the precious samples is key. Accurate technologies are available for Alzheimer’s disease (AD), but no platform can measure all the...
by Clinical Neuropsychologist | Friday, November 22, 2024 | Dementia
Abstract BACKGROUND This study examines whether phosphorylated plasma Tau217 ratio (pTau217R) can predict tau accumulation in different brain regions, as measured by positron emission tomography (PET) standardized uptake value ratio (SUVR), for staging...
by Clinical Neuropsychologist | Friday, November 22, 2024 | Dementia
Abstract INTRODUCTION While the role of apolipoprotein E (APOE) ε4 in Alzheimer’s disease (AD) susceptibility has been studied extensively, much less is known about the differences in disease presentation in APOE ε4 carriers versus non-carriers. METHODS To help...
by Clinical Neuropsychologist | Thursday, November 21, 2024 | Dementia
Abstract BACKGROUND Peak-width of skeletonized mean diffusivity (PSMD), a neuroimaging marker of cerebral small vessel disease (SVD), has shown excellent instrumental properties. Here, we extend our work to perform a biological validation of PSMD. METHODS We included...
by Clinical Neuropsychologist | Wednesday, November 20, 2024 | Dementia
Abstract Amyloid-PET quantification through the tracer-independent Centiloid (CL) scale has emerged as an essential tool for the accurate measurement of amyloid-β (Aβ) pathology in Alzheimer’s disease (AD) patients. The AMYPAD consortium set out to integrate...
